We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+0.53%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$241M
AUM Growth
+$23.2M
Cap. Flow
+$29.8M
Cap. Flow %
12.35%
Top 10 Hldgs %
74.61%
Holding
31
New
8
Increased
10
Reduced
8
Closed
3

Top Buys

1
AMRN
Amarin Corp
AMRN
+$16.2M
2
LGND icon
Ligand Pharmaceuticals
LGND
+$8.57M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$7.81M
4
QDEL icon
QuidelOrtho
QDEL
+$6.59M
5
XERS icon
Xeris Biopharma Holdings
XERS
+$5.54M

Top Sells

1
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$12.3M
2
EOLS icon
Evolus
EOLS
+$10.9M
3
ADMA icon
ADMA Biologics
ADMA
+$4.34M
4
AVTX icon
Avalo Therapeutics
AVTX
+$2.57M
5
OPTN
OptiNose
OPTN
+$2.18M

Sector Composition

1 Healthcare 94.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMYT
1
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$52.4M 21.74%
6,338,200
+268,425
+4% +$2.42M
CTIC
2
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$21.9M 9.07%
4,684,404
-4,115,954
-47% -$12.3M
XERS icon
3
Xeris Biopharma Holdings
XERS
$1.52B
$20.3M 8.41%
7,924,056
+2,267,683
+40% +$5.54M
AMRN
4
Amarin Corp
AMRN
$292M
$16.2M 6.7%
+245,636
New +$16.2M
OVID icon
5
Ovid Therapeutics
OVID
$455M
$13.2M 5.49%
4,218,069
+211,884
+5% +$667K
ADMA icon
6
ADMA Biologics
ADMA
$2.02B
$13.1M 5.41%
7,131,808
-2,779,769
-28% -$4.34M
ATRS
7
DELISTED
Antares Pharma, Inc.
ATRS
$12.8M 5.32%
3,130,192
+832,832
+36% +$3.02M
CFMS
8
DELISTED
Conformis, Inc. Common Stock
CFMS
$10.8M 4.47%
691,255
+100,502
+17% +$1.65M
APEN
9
DELISTED
Apollo Endosurgery, Inc.
APEN
$10.2M 4.25%
1,693,834
+542,671
+47% +$3.31M
XGN icon
10
Exagen
XGN
$106M
$9M 3.73%
1,121,040
+262,473
+31% +$2.26M
ENTA icon
11
Enanta Pharmaceuticals
ENTA
$400M
$8.54M 3.54%
+119,972
New +$7.81M
LGND icon
12
Ligand Pharmaceuticals
LGND
$6.08B
$8.29M 3.44%
+118,141
New +$8.57M
OPTN
13
DELISTED
OptiNose
OPTN
$7.23M 3%
195,094
-61,188
-24% -$2.18M
QDEL icon
14
QuidelOrtho
QDEL
$1.19B
$6.95M 2.88%
+61,791
New +$6.59M
EOLS icon
15
Evolus
EOLS
$377M
$6.58M 2.73%
586,224
-1,276,872
-69% -$10.9M
ATYR
16
aTyr Pharma
ATYR
$50M
$3.22M 1.33%
601,580
+76,049
+14% +$431K
DMAC icon
17
DiaMedica Therapeutics
DMAC
$393M
$2.99M 1.24%
1,197,245
+2,575
+0.2% +$7.3K
SYBX
18
DELISTED
Synlogic
SYBX
$2.55M 1.06%
70,942
– –
RZLT icon
19
Rezolute
RZLT
$444M
$2.53M 1.05%
748,702
-59,703
-7% -$230K
URGN icon
20
UroGen Pharma
URGN
$1.96B
$2.34M 0.97%
+268,833
New +$2.1M
SRGA
21
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$2.24M 0.93%
+245,856
New +$3.74M
CELC icon
22
Celcuity
CELC
$4.31B
$2.24M 0.93%
239,433
– –
CDTX
23
DELISTED
Cidara Therapeutics
CDTX
$2.08M 0.86%
124,826
+9,249
+8% +$157K
XOMA
24
DELISTED
Xoma
XOMA
$1.03M 0.43%
36,803
-9,223
-20% -$210K
AERI
25
DELISTED
Aerie Pharmaceuticals
AERI
$854K 0.35%
+93,900
New +$724K
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Stonepine Capital Management held 31 positions worth $241M, up 11% from $218M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Stonepine Capital Management deployed $29.8M of net new capital in Q1 2022, opening 8 new positions and adding to 10 existing holdings. Its largest new stake was Amarin Corp: 245,636 shares worth $16.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was CTI BioPharma Corp. (DE) Common Stock, an estimated $12.3M trimmed.

  • Stonepine Capital Management's largest Q1 2022 buy was Amarin Corp: 245,636 shares worth $16.2M.
  • Stonepine Capital Management added most to Xeris Biopharma Holdings in Q1 2022, an estimated $5.54M increase.
  • Stonepine Capital Management's biggest Q1 2022 reduction was CTI BioPharma Corp. (DE) Common Stock, cutting an estimated $12.3M.
  • Stonepine Capital Management fully exited Avalo Therapeutics in Q1 2022, selling an estimated $2.57M.
  • Stonepine Capital Management's ten largest holdings make up 75% of its $241M portfolio in Q1 2022.
  • Stonepine Capital Management opened 8 new positions and closed 3 in Q1 2022.
  • Stonepine Capital Management's portfolio value rose 11% quarter-over-quarter to $241M.

Based on Stonepine Capital Management's 13F filing for Q1 2022, filed 16 May 2022.